The relation between Ring Box-1 protein overexpression and tumor grade and stage in bladder urothelial cell carcinoma

Çelik, Zeliha Esin; Kaynar, Mehmet; Karabağlı, Pınar; Gergerlioglu, Nursadan; Göktaş, Serdar

doi:10.3233/cbm-170002

Cited by 4 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 9 studies including 1002 patients were eligible in this analysis ultimately. [6–10, 16, 19–21] The flow diagram was shown in Figure 1. All researches were published from June 2013 to October 2021.…”

Section: Resultsmentioning

confidence: 99%

Clinicopathological and prognostic role of ROC1 in neoplasms: A PRISMA-compliant systematic review and meta-analysis

Shen¹,

Wang²,

Qiu³

et al. 2022

Medicine

View full text Add to dashboard Cite

Background: Regulator of cullins 1 (ROC1) is frequently overexpressed in multiple tumors, and many pieces of research demonstrate that ROC1 is associated with the prognosis and development of a diversity of neoplasms and it is able to serve as a promising prognostic biomarker. Here we performed this meta-analysis to evaluate the prognostic and clinicopathological significance of ROC1 in patients suffering from cancer. Methods: We searched Pubmed, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and WanFang database. The role of ROC1 in cancers was evaluated by pooled hazard ratios (HRs), odd ratios (ORs) and 95% confidence intervals (CIs). Results: In total, 9 studies including 1002 patients were enrolled in this analysis. The pooled results showed that patients with high expression of ROC1 had poor overall survival (OS) (HR: 2.04, 95% CI: 1.48–2.60, P < 0.001) and recurrence-free survival (RFS) (HR: 1.727, 95% CI: 0.965–2.488, P < 0.001). Additionally, elevated expression of ROC1 was significantly correlated with advanced clinical Tumor Node Metastasis stage (OR: 2.708, 95% CI: 1.856–3.951, P < 0.001), positive lymph node metastasis (OR: 1.968; 95% CI: 1.294–2.993, P = .002), large tumor size (OR: 1.522, 95% CI: 1.079–2.149, P = .017) and poor tumor differentiation (OR: 2.448, 95% CI: 1.793–3.344, P < 0.001). Conclusions: Elevated ROC1 expression predicted worse prognosis and advanced pathological parameters in various cancers. ROC1 was a significant prognostic biomarker for poor survival in human cancers.

show abstract

Section: Resultsmentioning

confidence: 99%